Disability News and Research

RSS

Repeated pregnancies may increase cardiovascular disease

The study was designed to measure the blood pressure responses to phenylephrine and to acute stress in conscious age-matched repeatedly breed (RB) and virgin rats.

19 Apr 2004

Menthol in topical creams relieves Osteoarthritis pain

A new study extends previous research and examines the effects of a topical cream consisting of cetylated fatty acids, along with the addition of menthol, on pain and functional performance in patients with knee osteoarthritis over the course of one week.

19 Apr 2004

Back-pain sufferers cost US more than $100 billion annually

Back-pain sufferers in America cost this country more than $100 billion annually in medical bills, disability and lost productivity at work. And 80 percent of Americans will battle back pain at some point in their lives, making it the number two reason for doctor visits, after coughs and other respiratory infections, Newsweek reports.

18 Apr 2004

Drug's ability to reverse acute ischemic stroke

Ischemic stroke patients who arrive at the hospital too late to receive currently available treatment options might someday have a new treatment option. Northwestern Memorial Hospital is the only site in Chicago to participate in a phase III trial of abciximab (ReoPro - Centocor/Eli Lilly and Company), which seeks to determine the drug's ability to improve neurological function and minimize disability in patients who present with an acute ischemic stroke.

13 Apr 2004

Why business is bad for your health

Downsizing in the workplace has been associated with increased sickness absence. However, few data are available on the possible health effects, on individuals, of rapid expansion.

11 Apr 2004

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

6 Apr 2004

New research suggest that steroid treatment for osteoarthritis knee suffers may not progress disease as previously thought

Steroid treatment for osteoarthritis knee suffers was thought to progress the disease, but that belief has been overturned following a review of the literature by researchers at The University of Auckland. Associate-Professor Bruce Arroll, from the School of Population Health at the University, says that osteoarthritic knee pain is one of the leading causes of disability amongst older people.

30 Mar 2004

£1.6m for research into a possible cure for muscular dystrophy

A consortium which includes Oxford researchers has won £1.6m in government funding for ground-breaking research into a possible cure for muscular dystrophy.

30 Mar 2004

Simple blood tests which could predict the severity of osteoarthritis

Bristol researchers are hoping to develop simple blood tests which could predict the severity of osteoarthritis, a common, disabling joint condition which affects more than two million people in the UK.

29 Mar 2004

£35m needed to boost M.E./Chronic Fatigue Syndrome research

National charity Action for M.E. is asking the government for £35 million to find a cure for M.E. - also known as Chronic Fatigue Syndrome. With government plans to boost medical research funding to £1.2bn per year M.E. research must be considered a priority area of investment.

27 Mar 2004

Liverpool scientist presents chronic illness study to House of Commons

A social scientist from the University of Liverpool has visited the House of Commons to present preliminary findings of an innovative research project to MPs.

22 Mar 2004

Nickel-Titanium Clot-buster reverses vessel damage

A novel corkscrew-like device that mechanically removes clots from the brain has shown promise in recanalizing occluded vessels and reversing damage caused by ischemic stroke, according to researchers at the 29th International Stroke Conference.

20 Mar 2004